This is an international site for AFINITOR® (everolimus) and is intended for Health Care Professionals outside the U.S. The information on the site is not country-specific, and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country

I am a healthcare professional outside of the US I am a US Resident I am a patient outside of the US

AFINITOR® (everolimus) Logo | AFINITOR.com
AFINITOR is a once-daily oral inhibitor of mTOR (mammalian target of rapamycin) for patients with advanced renal cell carcinoma (RCC) whose disease has progressed on or after treatment with VEGF-targeted therapy
Afinitor now approved in the EU!
Afinitor International Website  |  For Healthcare Professionals Outside the U.S.  |  US Residents
Mechanism of Action
mTOR Inhibitors

• Cell Proliferation

• Angiogenesis

• Cell Metabolism


Stay informed on the latest information, including news related to AFINITOR and other updates.

Register for Afinitor Updates
Afinitor Approved Countries

mTOR Inhibitors

mTOR inhibitors may play an important role in the management of advanced renal cell carcinoma

mTOR inhibition has been proven to result in:

  • Reduced tumor cell growth and proliferation
  • Decreased tumor angiogenesis
  • Inhibited cell metabolism

One potential benefit of mTOR inhibitors is that they work downstream from other agents available to treat renal cell carcinoma, at the point where a number of important signaling pathways that are activated in renal cell carcinoma converge (see figure).

See how AFINITOR works. View the key data about AFINITOR, including results for progression-free survival and demonstrated efficacy.

Next: Cell Proliferation